TELA - NASDAQ

TELA Bio, Inc.

TELA Bio, Inc.

TELAยทNASDAQ

$1.14

+0.44%
HealthcareMedical - Devices

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$50.78M
EPS-0.8300
P/E Ratio-1.37
Earnings Date05/06/2026
TELA Bio, Inc.

TELA Bio, Inc. Fair Value Envelope

TELA ยท NASDAQ

Our analysis suggests that TELA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.135, this represents a potential HIDDEN relative to our calculated worth for TELA Bio, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.135

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.0B
+ Cash & Equivalents$50.8M
Firm Value-$988.8M
- Debt$55.7M
Equity Value-$1.0B
/ Shares Outstanding39,616,400B
DCF Value-$26
OVERVALUED BY 2423%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$37.4M
-$49.7M
-$65.9M
-$87.5M
-$116.0M
-$154.0M
-$204.3M
-$271.0M
-$359.6M
-$477.1M
Maintenance CapEx
-$118.9K
-$157.7K
-$209.3K
-$277.7K
-$368.4K
-$488.8K
-$648.6K
-$860.6K
-$1.1M
-$1.5M
Owner Earnings
-$37.6M
-$49.8M
-$66.1M
-$87.7M
-$116.4M
-$154.4M
-$204.9M
-$271.9M
-$360.7M
-$478.6M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$34.8M
-$42.7M
-$52.5M
-$64.5M
-$79.2M
-$97.3M
-$119.6M
-$146.9M
-$180.5M
-$221.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TELA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.